Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
ASSESSING THE ASSOCIATION BETWEEN RISKY SEXUAL BEHAVIORS AND HEPATITIS C AMONG DRUG USERS RECENTLY RELEASED FROM INCARCERATION _______________ A Thesis Presented to the Faculty of San Diego State University _______________ In Partial Fulfillment of the Requirements for the Degree Master of Public Health with a Concentration in Epidemiology _______________ by Christiane-Rayna R. Lopez Summer 2013 iii Copyright © 2013 by Christiane-Rayna R. Lopez All Rights Reserved iv DEDICATION This thesis is dedicated to my parents, who have given me every opportunity to succeed, as well as their unconditional support and constant encouragement. v ABSTRACT OF THE THESIS Assessing the Association between Risky Sexual Behaviors and Hepatitis C among Drug Users Recently Released from Incarceration by Christiane-Rayna R. Lopez Master of Public Health with a Concentration in Epidemiology San Diego State University, 2013 Hepatitis C is the most common bloodborne infection in the United States, with the primary mode of transmission being from injection drug use. Hepatitis C can also be transmitted sexually, but whether this is an efficient means for transmission is unclear. Although Hepatitis C transmission has been shown to be very low in low-risk, heterosexual, long-term, monogamous relationships, higher prevalences have been found among groups likely to be engaging in high-risk sexual behavior, such as men who have sex with men, sex workers, and patients of STI clinics. As drug users and incarcerated populations have high Hepatitis C prevalences compared to the general population, and have reported high rates of risky sexual behaviors, it would be possible for sexual transmission of Hepatitis C to occur within these vulnerable populations. This study uses cross-sectional data from the HIV/HEPC study conducted as part of the National Institute for Drug Abuse's Criminal Justice Drug Abuse Treatment Studies to assess the relationship between engaging in risky sexual behaviors and Hepatitis C. Data from 614 participants recently released from incarceration were analyzed. Risky sexual behavior was defined as the number of sexual partners and engaging in unprotected sex with a casual partner, injection drug user, or while self or partner exchanged sex for money, drugs, or gifts, within the six months before incarceration. Hepatitis C status was determined using an ELISA antibody assay. Other independent variables included were history of sexually transmitted infections, history of injection drug use, ever having a tattoo, ever having a blood transfusion, total years incarcerated, age, race, and sex. This study did not find a significant association between risky sexual behaviors and Hepatitis C test result after adjusting for other variables; however, its findings suggest that more research should be done to assess this relationship within different groups, in the context of different drugs, and within correctional facilities themselves. vi TABLE OF CONTENTS PAGE ABSTRACT ...............................................................................................................................v LIST OF TABLES ................................................................................................................. viii LIST OF FIGURES ................................................................................................................. ix ACKNOWLEDGEMENTS .......................................................................................................x CHAPTER 1 INTRODUCTION .........................................................................................................1 Background ..............................................................................................................1 Statement of the Problem .........................................................................................2 Purpose of the Study ................................................................................................2 Hypothesis................................................................................................................2 Basic Assumptions ...................................................................................................3 Definition of Terms..................................................................................................3 2 LITERATURE REVIEW ..............................................................................................4 Overview ..................................................................................................................4 Sexual Transmission of Hepatitis C .........................................................................5 Injection Drug Use and Hepatitis C .........................................................................7 Drug Use and Risky Sexual Behavior .....................................................................8 The Incarcerated Population ....................................................................................9 Hepatitis C in Incarcerated Populations .................................................................10 Drug Users in Incarcerated Populations ................................................................10 Risky Behaviors in Incarcerated Populations ........................................................11 Hepatitis C Prevention and Control in Correctional Facilities ..............................13 Conclusion .............................................................................................................14 3 METHODS ..................................................................................................................16 Study Design ..........................................................................................................16 Study Population and Eligibility ............................................................................17 Data Collection and Measures ...............................................................................17 vii Study Variables ......................................................................................................19 Outcome and Main Variable of Interest...........................................................19 History of STIs .................................................................................................20 History of Injection Drug Use..........................................................................20 Other HCV Risk Behaviors .............................................................................21 Total Years Incarcerated ..................................................................................21 Sociodemographic Variables ...........................................................................21 Statistical Analysis .................................................................................................21 4 RESULTS ....................................................................................................................23 5 DISCUSSION ..............................................................................................................31 Key Findings ..........................................................................................................31 Limitations .............................................................................................................33 Strengths ................................................................................................................35 Implications and Future Research ..........................................................................35 REFERENCES ........................................................................................................................38 viii LIST OF TABLES PAGE Table 1. Descriptive Statistics for Covariates of Interest in Drug Offenders Recently Released from Incarceration, n=614 ............................................................................24 Table 2. Descriptive and Bivariate Statistics for Covariates of Interest in Drug Offenders Recently Released from Incarceration, by Sexual Behavior Category, n=614 ...........................................................................................................26 Table 3. Simple Logistic Regression of Covariates of Interest with Hepatitis C Test Result a for Drug Offenders Recently Released from Incarceration, n=614 ................28 Table 4. Final Multivariable Logistic Regression Model of Variables of Interest with Hepatitis C Test Result a for Drug Offenders Recently Released from Incarceration, n=614 ....................................................................................................30 ix LIST OF FIGURES PAGE Figure 1. Final sample size for present analysis. .....................................................................18 x ACKNOWLEDGEMENTS I would like to thank my committee members, Dr. Alcaraz, Dr. Ferran, and Dr. Mobley, for their guidance and for sharing their knowledge with me. I would also like to thank my family and friends for their amazing support these past two years. 1 CHAPTER 1 INTRODUCTION This chapter will discuss background information on Hepatitis C in the U.S., state the problem this thesis will address, and the describe the purpose and hypothesis of this study. BACKGROUND Hepatitis C (HCV) is the most common bloodborne infection in the United States, with approximately 2% of the population, or 3.2 million people, chronically infected (Centers for Disease Control [CDC], 2011a). HCV can be asymptomatic, and without treatment, it can result in hepatic fibrosis, cirrhosis, and liver cancer. It is the leading cause for liver transplantation and death from liver disease (Chak, Talal, Sherman, Schiff, & Saab, 2011; United States Department of Health & Human Services [HHS], 2011). HCV is transmitted through percutaneous exposure to blood from an infected person, and is usually spread by blood transfusion from infected donors or the use of contaminated syringes for illicit drug use. Occupational, perinatal, and sexual transmission of HCV can also occur. In the U.S., injection drug use is the primary mode of transmission for Hepatitis C. Injection drug use accounts for 68% of current infections and more than 60% of new cases (Shepard, Finelli, & Alter, 2005; Thorpe et al., 2002). Injection drug users (IDU) are at a much higher risk for HCV due to risky behaviors, such as sharing syringes and drug paraphernalia, that increase their exposure to infected blood. Research on the role of sexual behavior in the transmission of Hepatitis C has been controversial. According to the CDC (2011a), sexual transmission of HCV is possible, but inefficient. However, higher rates of HCV have been found among groups likely to be engaging in high-risk sexual behaviors, such as men who have sex with men (MSM), sex partners of people infected with HIV, prostitutes, and patients attending STD clinics (Thomas et al., 1994). Rough sexual acts and sexually transmitted infections can increase exposure to infected blood and create an opening for HCV to be transmitted. 2 The incarcerated population is disproportionately affected by HCV compared to the general US population, with estimates of 16-41% of inmates infected versus 2% of the nonincarcerated population (CDC, 2011b). In correctional facilities, one out of every three individuals is infected with HCV. The higher rates of HCV among the incarcerated population are often attributed to a higher rate of injection drug users entering prison and increased frequency of high-risk sexual behaviors, tattoos, and non-injection drug use among those incarcerated (Burton, Reilly, & Penman, 2010). STATEMENT OF THE PROBLEM Both Hepatitis C and risky sexual behaviors are prevalent among illicit drug users and incarcerated populations. It is possible for HCV to be acquired through injection drug use and then spread through sexual activities. This represents an important public health problem as drug offenders make up a significant proportion of those incarcerated and may continue to engage in risky drug sharing and sexual behaviors after reentering the community. Given the higher prevalence of Hepatitis C and the increased likelihood of behavioral risk factors in drug users and incarcerated populations, understanding the role of risky sexual activity behaviors on HCV transmission is important to develop and implement effective prevention and control programs to screen, treat, and educate incarcerated drug users reentering the community. PURPOSE OF THE STUDY The purpose of this thesis is to assess the relationship between positive Hepatitis C status and risky sexual behavior in a population of drug users recently released from incarceration. The goal of this thesis is to identify demographic and behavioral differences in sexual and HCV risk behaviors between drug users who received a positive HCV test result, compared to those who received a negative test result. This study uses data from the National Institute on Drug Abuse's Criminal Justice Drug Abuse Treatment Studies (NIDA CJ-DATS) HIV/HEPC study. HYPOTHESIS There is an association between risky sexual behaviors and positive HCV status. Among drug users recently released from incarceration, those reporting risky sexual 3 behaviors were more likely to have tested positive for HCV, compared to those who reported no risky sexual behaviors. BASIC ASSUMPTIONS This study assumes participants answered the survey questions truthfully, and their responses were coded and entered correctly. DEFINITION OF TERMS The following is a list of terms commonly used in this thesis: 1. HCV: Hepatitis C virus--causes liver disease that often becomes a chronic condition and can lead to cirrhosis and liver cancer. 2. HIV: Human immunodeficiency virus--severely damages the immune system by infecting CD4+ T cells, leaving the body more susceptible to infections. This can lead to acquired immune deficiency syndrome (AIDS). 3. IDU: Injection drug user--an individual who uses syringes to administer illicit drugs 4. NIDU: Non-injection drug user--an individual who takes illicit drugs, but does not administer the drugs using syringes 5. MSM: Men who have sex with men 6. STI/STD: Sexually transmitted infection or sexually transmitted disease 7. NIDA CJ-DATS: National Institute on Drug Abuse's Criminal Justice Drug Abuse Treatment Studies 8. ELISA: Enzyme-linked immuno assay--a laboratory test commonly used to detect antibodies in a sample of blood 9. Anti-HCV: Antibodies to Hepatitis C 4 CHAPTER 2 LITERATURE REVIEW This chapter will discuss key findings in the literature on Hepatitis C and its relationship with sexual behavior, drug use, and incarcerated populations. OVERVIEW Hepatitis C is the most common bloodborne infection in the United States. Of the estimated 3.2 million people infected nationwide, 65-75% are unaware of their infection status and are not receiving care and treatment (HHS, 2011). HCV is a leading cause of chronic liver disease and can lead to hepatic fibrosis, cirrhosis, and hepatocellular carcinoma. It is also the leading cause for liver transplantation, liver cancer, and death from liver disease, with Hepatitis C-related mortality increasing by 123% from 1995 to 2004 (Awofeso, 2010; Chak et al., 2011; HHS, 2011). Between 60 and 70% of acute HCV infections are asymptomatic and 60-85% of acute cases progress to chronic infection. Of those chronic Hepatitis C infections, between 10 and 20% will develop complications of chronic liver disease within 20 to 30 years and 1-5% will develop liver cancer. There are more than 500,000 new cases of liver cancer each year, 22% of which can be attributed to HCV infection (Ghany, Strader, Thomas, & Seeff, 2009; Lavanchy, 2011). There is no vaccine and no effective post-exposure prophylaxis for HCV. Chronic Hepatitis C can be treated, usually with a combination of interferon and ribavirin. But the price of current treatment regimens is high; a typical 48-week course of therapy for the most common genotype of HCV would cost $25,000 (Shepard et al., 2005). The annual costs of acute and chronic Hepatitis C are currently estimated to be over $600 million, and total costs are estimated to be $184 billion between 2010-2019 (Lavanchy, 2011). Hepatitis C is primarily transmitted through percutaneous exposure to infected blood. Before blood screening became available in 1992, HCV was most commonly transmitted through blood transfusion; currently, the leading means of HCV transmission in the U.S. is injection drug use (CDC, 2012). HCV can also be transmitted through needle-stick injuries, 5 during birth to an HCV-infected mother, and infrequently through sex with an HCV-infected partner and sharing of personal items contaminated with infectious blood. Risk groups for Hepatitis C include injection-drug users (IDUs), men who have sex with men (MSM), and incarcerated populations. Higher prevalence of HCV is also seen among African-Americans and persons born between 1945-1965. The CDC (2012) recently recommended that all persons in this age range be tested for Hepatitis C as this age group is five times more likely than those in other adult age groups to be infected, though the reasons why there are such high rates among baby boomers is not completely understood. SEXUAL TRANSMISSION OF HEPATITIS C Research on sexual transmission of Hepatitis C has been controversial. According to the CDC (2011a), sexual transmission of HCV is possible, but not efficient. Studies in lowrisk heterosexual relationships with long-term monogamous partners have shown the frequency of sexual transmission of HCV to be very low (Hahn, 2007; van de Laar et al., 2007). A cross-sectional study of 80 patients with chronic HCV-associated liver disease and their spouses found sexual transmission to be possible in only 2 (2.5%) spouses, despite the high percent of long sexual relationships and the high frequency of unprotected sex (Neumayr, Propst, Schwaighofer, Judmaier, & Vogel, 1999). The HCV Partners Study found the prevalence of infection among sexual partners of 500 HCV-positive persons to be 4% (Terrault et al., 2013). The prevalence of infection potentially attributable to sexual contact was 0.6%, as 3 couples had partners infected with the same HCV strain as their HCVpositive counterparts. As the risk of sexual transmission of HCV in long-term monogamous heterosexual couples reporting no other HCV risk factors has been shown to be low, the CDC advises that such couples do not need to change their sexual practices (CDC, 2010). However, higher rates of HCV have been found among MSM, sex partners of people infected with HIV, prostitutes, and patients attending STD clinics. These groups are likely to be engaging in high-risk sexual behaviors, such as having unprotected anal intercourse, having multiple sex partners, and using rough sexual techniques, and may be co-infected with other STIs. Risky sexual behaviors and STI co-infection have been identified as potential risk factors for sexual transmission of HCV as such behaviors can lead to blood-toblood contact and STIs can create a portal of entry through the anal or genital mucosal 6 barrier. A study by Thomas et al. (1994) determined the seroprevalence of HCV among noninjection-drug using patients attending Baltimore STD clinics to be 9.7%. In men, the presence of Hepatitis C antibodies was found to be associated with age, failure to use condoms, having a history of gonorrhea, and the presence of HIV antibodies or Hepatitis B antibodies. For women, the presence of HCV antibodies was significantly associated with having more than one male sex partner in the month before their visit and the presence of antibodies for Hepatitis B or HIV. The frequency of sexual transmission of HCV has been shown to increase in the setting of HIV. In the U.S., HCV co-infection occurs in 15-30% of HIV-infected individuals (Burton et al., 2010). HCV and HIV share common routes of transmission, and while IDU is considered the most important risk factor for being infected with both viruses, HCV is increasing in HIV-infected men who have sex with men. Results from a large prospective longitudinal cohort study looking at HCV prevalence and incidence in MSM in Amsterdam from 1984-2003 suggest an increase in HCV incidence over time among HIV-positive MSM, but not among HIV-negative MSM (van de Laar et al., 2007). MSM who were infected after 2000 and reported no injection drug use were found to carry MSM-specific HCV strains significantly different from strains circulating among IDUs. In a case control study of HIV positive MSM, cases co-infected with HCV had significantly more sexual partners than controls, reported more high-risk mucosally traumatic sexual behavior, and were more likely to have had a STI (Danta et al., 2007). HIV infection facilitates HCV transmission by increasing both viral infectiousness due to higher viral loads, and viral susceptibility through its detrimental effects to the immune system. Compared to HIV negative persons, HIV positive persons have higher HCV load in the blood and semen (Hahn, 2007). Worse health outcomes are associated with HIV/HCV co-infection than HCV infection alone. In coinfected persons, the rate of spontaneous clearance of HCV is lower, occurring in only 5%10% of co-infected persons compared to 15%-35% in those only infected with HCV (Strader, 2005). Co-infection is also associated with accelerated progression of cirrhosis, liver failure, and hepatocellular carcinoma, and less favorable outcomes to HCV treatment (Ghosn et al., 2008). 7 INJECTION DRUG USE AND HEPATITIS C For over 30 years, the primary mode of transmission for Hepatitis C in the U.S. has been injection drug use, accounting for 68% of current infections and more than 60% of new cases (Shepard et al., 2005; Thorpe et al., 2002). Current estimates of HCV incidence in young IDUs in the US are between 9-35% a year, with one in five IDUs becoming infected within the first two years of injection drug use and more than one in three becoming infected within the first five years. (Amon et al., 2008; Hahn, 2007). The prevalence of HCV has been found to be associated with increases in age, years injecting, and frequency of injection drug use, with HCV prevalence among long term IDUs ranging between 70-90% (Hagan, Thiede, & Des Jarlais, 2005; Thorpe et al., 2002). Sharing syringes and drug paraphernalia used in the injection process, such as cookers (used to heat and melt the drug for injection), cotton (used to filter the drug as it is drawn up into a syringe), and rinse water, and the process of backloading (using one syringe to squirt the drug solution into the back of other syringes) have been found to increase the risk of HCV transmission in IDUs. A prospective study of young IDUs in San Francisco found that needles and other equipment were commonly shared among young IDUs; 67% reported having ever borrowed a needle/syringe, and 85% reported having ever shared drug equipment (Hahn et al., 2002). The study also found that sharing needles with an HCVinfected person and sharing nonsterile drug equipment were independent risk factors for HCV, and forming injection or sexual partnerships involving the sharing of drug paraphernalia were common among young IDUs. Young IDUs may engage in such risk behaviors due to paraphernalia laws that might discourage them from carrying their own sterile equipment, and sharing needles may demonstrate reciprocity and trust in relationships. In another prospective study of young IDUs in Chicago, 74% of IDUs reported sharing injection drug paraphernalia in the 6 months prior to the study (Thorpe et al., 2002). The study also found that sharing cookers and sharing rinse water were independent predictors of seroconversion, indicating IDUs who share paraphernalia other than syringes are at increased risk for HCV seroconversion. Cookers have been found to be shared among IDUs more often than other equipment as cookers are kept and reused longer than cotton filters and rinse water. 8 Because of shared routes of transmission, many people infected with HIV are also coinfected with HCV, with the majority of co-infected patients being injection drug users (Strader, 2005). As HCV can be transmitted through small-volume percutaneous exposure more easily than HIV, data suggests that more than half of people infected with HIV via percutaneous exposures are also infected with HCV. In the U.S., IDUs are more likely than other HIV-positive groups to be co-infected; 50 to 90% of HIV-positive IDUs are co-infected with HCV, compared with less than 20% among those infected with sexually transmitted HIV (Hagan et al., 2005; Strader, 2005). HIV/HCV co-infection has been associated with lower rates of spontaneous clearance of HCV and more rapid progression to cirrhosis, liver failure, and liver cancer, making co-infection among IDUs of increasing public health concern. DRUG USE AND RISKY SEXUAL BEHAVIOR Studies have shown drug users to frequently engage in risky sexual behaviors, such as having multiple partners, having unprotected sex, and exchanging sex for money or drugs. In a study of 101 IDUs in Milwaukee, Wisconsin, 72 reported having sex with multiple partners in the three months before the study; more than half reported having three or more different sexual partners and one-third reported having six or more partners (Somlai, Kelly, McAuliffe, Ksobiech, & Hackl, 2003). Ninety-seven of the 100 participants who reported having vaginal intercourse reported not using protection. In a study of drug users in Baltimore, 40% reported having a sex partner who was an IDU and less than half reported consistent condom use (Sherman & Latkin, 2001). In a study of 407 patients at three drug treatment clinics in Texas, those who preferred crack as their drug of choice were more likely to report previous STIs, have bought or sold sex for drugs or money, and have had double the number of sexual partners in the past four weeks (Ross, Hwang, Zack, Bull, & Williams, 2002). As sexual transmission of HCV has been found in groups likely to be engaging in risky sexual behaviors, such activities increase their susceptibility to infection with HIV, and STIs and may play a role in the transmission of HCV among drug users. There may be differences in the likelihood of engaging in risky sexual behaviors between IDUs and NIDUs. A prospective study of non-injection drug users (NIDUs), found that transition to injection drug use was associated with increased likelihood of risky sexual 9 behaviors (Mackesy-Amiti, Boodram, Williams, Ouellet, & Broz, 2012). In men, transition to injection drug use was associated with increased likelihood of unprotected vaginal or anal sex, unprotected sex with casual partners, trading and buying sex, and having an IDU sex partner. In women, transition to injection drug use was associated with increased likelihood of trading sex and having an IDU sex partner. Engaging in riskier drug behaviors may lead to engaging in riskier sexual behaviors, increasing the risk of transmission of HCV, HIV, and STIs in drug-using populations. THE INCARCERATED POPULATION The main correctional institutions holding incarcerated persons are jails and prisons. Jails are usually run by counties and municipalities and hold individuals awaiting trial or serving short-term sentences for misdemeanors; prisons are often run by state or federal governments and hold individuals convicted of crimes and receiving sentences of a year or more (Binswanger, Krueger, & Steiner, 2009). At the end of 2011, over 2.2 million Americans were incarcerated (Glaze & Parks, 2012). Over 1.5 million adults, or 1 in every 107, were in prison. Over 700,000 adults were in jail at the end of 2011 and from midyear 2009 to midyear 2010, almost 13 million persons were admitted to local jails (Minton, 2011). Compared to the general population, the incarcerated population has a higher burden of most chronic medical conditions and infectious diseases (CDC, 2003a). In a crosssectional study using data from the 2002 Survey of Inmates in Local Jails, the 2004 Survey of Inmates in State and Federal Correctional Facilities, and the 2002-2004 National Health Interview Survey Sample Adult Files, inmates were found to have a higher prevalence of hypertension, diabetes, myocardial infarction, asthma, arthritis, cervical cancer and Hepatitis (Binswanger et al., 2009). Inmates are at increased risk for poor health outcomes due to circumstances before and during incarceration. Inmates are more likely to come from disadvantaged backgrounds, have low levels of education, and lack health care coverage. Inmates are exposed to infectious diseases through risky drug injection and sexual behaviors, and are more likely to have high levels of smoking, drinking, and illicit drug use. Inmates are more likely to have mental health and neurological disorders such as schizophrenia, depression, and epilepsy, and more than half of inmates show symptoms of psychiatric disorders, with the prevalence of major depression and psychotic disorders being four to 10 eight times higher among inmates than the general population (Rich, Wakeman, & Dickman, 2011). In correctional facilities, inmates can suffer from poor nutrition and limited physical activity, high levels of stress, anxiety, and sleep deprivation (Binswanger et al., 2009). These factors leave inmates susceptible to becoming chronically ill, acquiring infections, and transmitting diseases, both within correctional facilities and the communities into which they are released. HEPATITIS C IN INCARCERATED POPULATIONS As there are no mandated screening programs for Hepatitis C, it is difficult to obtain its true prevalence in the incarcerated population. In a review of several studies investigating HCV in high risk populations, Chak et al. (2011) found the prevalence of HCV in incarcerated populations to range from 23.1% to 39.4%. According to the CDC, between 16% and 41% of inmates have ever been infected with HCV, and 12-31% of inmates have chronic HCV infection (CDC, 2011b). Of the more than 3 million people infected with HCV in the U.S., 29-43% pass through a correctional system each year (Spaulding & Thomas, 2012). HCV mortality among the incarcerated population has been increasing. A study of mortality of male prisoners in the Texas Department of Criminal Justice found that the proportion of deaths accountable to HCV increased from 1% in 1994-1997 to 8% in 2003 (Harzke et al., 2009). HCV was recorded as the underlying cause of death for over 3% of prisoner deaths and as an intervening or contributing cause for 9% of deaths in the sample during the study period. DRUG USERS IN INCARCERATED POPULATIONS The higher rates of HCV among the incarcerated population compared to the general population is often attributed to a higher rate of IDUs entering prison (Burton et al., 2010). A study of male prisoners in Rhode Island found the prevalence of HCV to be 23.1%, and HCV infection was found to be significantly associated with injection drug use (Macalino et al., 2004). More serious drug users are housed in the correctional system than in any other institution (Freudenberg, 2001). Seventeen percent of state and 48% of federal prison populations are made up of drug offenders, and about half of state and federal prisoners meet criteria for drug dependence and substance abuse (Carson & Sabol, 2012; Mumola & 11 Karberg, 2006). Between 73-83% of prison inmates report a history of drug use, and 45-57% reported drug use in the month prior to incarceration (Weinbaum, Sabin, & Santibanez, 2005). Although a significant number of inmates are in need of substance abuse treatment, only 7-17% of inmates who reported regular drug use before being incarcerated participated in some form of treatment (Chandler, Fletcher, & Volkow, 2009). Having substance abuse treatment programs available to inmates has the potential to prevent future incarcerations and transmissions of HCV infection as a link has been demonstrated between substance abuse, incarceration, and recidivism; in state prisons, 41% of first-time offenders used drugs regularly compared with 63% of second-time offenders and 81% of those who had five or more previous convictions (Spaulding et al., 2006). More effective drug treatment programs in correctional facilities targeting all inmates in need of treatment could reduce drug use among repeat offenders and reduce risk behaviors associated with transmitting HCV. RISKY BEHAVIORS IN INCARCERATED POPULATIONS The risk of sexual transmission of disease is higher in incarcerated populations compared to the non-institutionalized population. High rates of gonorrhea, Chlamydia, and syphilis have been found among entering inmates, and many inmates have reported multiple sex partners and inconsistent condom use both before incarceration and after release (Weinbaum et al., 2005). In a prospective study of 106 male prisoners by Morrow and the Project START Study Group (2009), 40% reported having multiple sex partners one month, three months, and 6 months after being released from prison. Around half of the participants reported having unprotected vaginal sex with casual female partners during the six-month follow up period following release from prison. Despite reporting engaging in risky sexual behaviors, most of the participants did not think they were at high risk for HIV. In another prospective study, 178 male prisoners in Mississippi, Rhode Island, and Wisconsin had urine and blood screening 6 months after being released from prison (Sosman et al., 2011). Twenty six percent of men were found to be infected with gonorrhea, chlamydia, trichomoniasis, HBV, or HCV. During the six-month period after release, 72% reported having multiple sexual partners, 32% reported having unprotected sex with multiple partners, and 75% reported having at least one risky sexual partner. A cross-sectional study of 111 HIV infected 12 patients receiving care in two Mississippi clinics found that having a history of incarceration was independently associated with HIV/HCV co-infection, and co-infected participants were more likely to report a history of gonorrhea (Burton et al., 2010). Risky sexual contact can occur during incarceration and increase the risk of spreading STIs among prisoners. A study on mandatory pre-release STD testing of 744 male inmates from an Ohio prison identified 53 new cases of STDs not identified through testing at intake. Of the 12% of inmates that reported having sex during the present prison term, 86% reported having multiple partners (Sieck & Dembe, 2011). Outbreaks of syphilis, Hepatitis B, and HIV have occurred among MSM within prison populations, and this represents a possible means of HCV transmission (Burton et al., 2010). Also, male prison rape may increase contact to infected blood and facilitate transmission of HCV as it often involves multiple assailants and trauma to the rectal mucosa. Of 40,419 jail inmates surveyed in 2007, 0.7% reported having nonconsensual sex with another inmate, an estimated 5,200 inmates nationwide (Beck & Harrison, 2008). As HIV has been proposed as a co-factor that enhances sexual transmission of HCV, HIV-infected prisoners may be more vulnerable to acquiring HCV infection through sexual contact or assault during incarceration. Tattooing is another risk behavior among inmates that can transmit HCV. Tattooing in prison can transmit HCV through the use of unsterilized equipment, such as guitar strings, paper clips, or sewing needles (Tohme & Holmberg, 2012). The prevalence of tattooing among incarcerated persons has been found to be up to 40% and is especially popular among drug users. Prisoners with a history of IDU have been found to be five times more likely to have a tattoo and were significantly more likely to have received the tattoo while in prison. In a study of 1062 injection drug users in New Mexico, 74.6% had tattoos and 37.6% reported receiving tattoos while incarcerated (Samuel, Doherty, Bulterys, & Jenison, 2001). As there is limited, if any, access to harm reduction methods such as condoms and sterilized needles in prison, such risk behaviors among inmates present a greater risk of transmission to other inmates and contacts in their communities after release. 13 HEPATITIS C PREVENTION AND CONTROL IN CORRECTIONAL FACILITIES Screening of individuals at risk for Hepatitis C, treatment of those with chronic HCV infection, and HCV interventions are needed in correctional settings in order to identify inmates with asymptomatic infection, reduce chronic liver disease and disability, and prevent further transmission to others. It is currently recommended that incarcerated persons with risk factors for HCV infection be screened (CDC, 2003a). However, in jails, HCV screening has not been routinely conducted as treatment could not realistically be provided for shortterm inmates (Spaulding & Thomas, 2012). HCV therapy may last for up to 48 weeks, whereas the median length of stay is 48 hours in short term correctional facilities. As time does not permit the majority of these individuals to start treatment before discharge, only about 1% could realistically be treated. As for prisons, 49 states have at least one prison that tests inmates, with 10 states offering routine testing in all facilities (Beck & Maruschak, 2004). Of 1584 state prison facilities, the majority (88%) reported testing targeted groups of inmates who were at risk, inmates who requested testing, or inmates who showed clinical symptoms; only 4% reported testing incoming inmates. Screening would have costly consequences for correctional facilities, as treating eligible patients could represent a 15% to 60% increase in the average state correctional system medical budget (Spaulding et al., 2006). Treatment for HCV is available in many prisons. In the 2000 Census of State and Federal Adult Correctional Facilities, 70% (1,104) of 1584 state adult correctional facilities reported having a policy to treat inmates, and most reported having a policy to treat HCVpositive inmates recommended for treatment (Beck & Maruschak, 2004). Between midyear 1999 and midyear 2000, 17,911 inmates had confirmed positive HCV tests; 4,750 inmates total were treated, and 3,082 of those were treated in 18 facilities in nine states and the District of Columbia. Although many prisons have policies to treat inmates for chronic Hepatitis C, not all inmates with HCV receive treatment. In order to receive treatment, inmates need to have enough time to complete treatment and have adequate follow-up during their sentence, which could take up to a year (Spaulding et al., 2006). For inmates at some facilities, this may require sentences of at least 15-18 months or deferring early-release programs into parole (Maru, Bruce, Basu, & Altice, 2008; Tan, Joseph, & Saab, 2008). Other 14 barriers to treatment include clinical contraindications, unstable mental or chronic illness, substance dependence, ongoing high risk behaviors, and lack of insurance once released. Effective transitional programs linking post-release inmates to community-based medical services are needed to ensure completion of treatment and follow-up. The Hepatitis C Continuity Program in New York is one example of a statewide program that operates through referral resources to provide released prisoners with access to health care facilities to continue treatment (Klein et al., 2007). Interventions for Hepatitis C could reduce the incidence of infections by giving inmates the knowledge and skills to prevent transmission to others after they are released. HCV prevention programs could be done at entry, before release, and integrated into other programs for HIV prevention and substance abuse treatment. An intervention study on 745 soon-to-be-released prisoners participating in the Prevention Case Management program for HIV prevention in Maryland found that over a four-year period, participants had significant increases in positive attitudes toward condoms and self-efficacy to use condoms and reduce injection drug use risk (Bauserman et al., 2003). A study of 522 soon-to-be-released male prisoners from four states participating in the Project START intervention for HIV, Hepatitis, and STI risks found significantly lower rates of unprotected sex after 6 months post-release for men in the multisession intervention compared to those in the single-session intervention (Wolitski & the Project START Writing Group, 2006). Despite the need for interventions addressing Hepatitis C, not all prisons have programs to implement them; only 20% of prisons reported having an HIV prison-based peer program, and 74% reported having drug and alcohol dependency, counseling, and awareness programs (Collica, 2007; Stephan, 2008). There is a need for comprehensive interventions available to inmates that integrate substance abuse services with HIV and Hepatitis C prevention programs to promote changes in risky drug and sexual behaviors in the community. CONCLUSION Sexual transmission of Hepatitis C can occur in groups engaging in risky sexual behaviors and has been found to be associated with having multiple partners, having unprotected sex, having rough sex, and being co-infected with STIs. IDUs and incarcerated persons are high risk groups for HCV and have reported higher rates of risky sexual behavior 15 than the general population. With at-risk drug users representing a significant proportion of the incarcerated population and entering jails and prisons at high rates, correctional institutions can serve to screen this vulnerable population, catch asymptomatic cases, start treatment, and run intervention programs before returning them to their communities. Prevention and control of HCV within correctional settings requires collaboration between prisons, local governments, public health departments, and community health care facilities as well as funding in order to ensure testing and treatment in-house and continuity of care after release. Research into the role of sexual transmission of HCV among incarcerated drug users can help to improve prevention and control programs and prevent transmission of infection in correctional settings and out in the community. 16 CHAPTER 3 METHODS This chapter will describe the design of the present study, the study population, how the data was collected and measured, the variables of interest, and the statistical analysis. STUDY DESIGN This thesis is a cross-sectional study using baseline survey data from the HIV/HEPC study conducted as part of the National Institute on Drug Abuse's Criminal Justice Drug Abuse Treatment Studies (NIDA CJ-DATS) (Inciardi, 2011). As this thesis conducts secondary analysis of publicly available data, no IRB approval was required. The CJ-DATS study was led by the University of Delaware and implemented by the University of Delaware, the University of Kentucky, and George Mason University from 2006 to 2008. The purpose of the CJ-DATS HIV/HEPC study was to evaluate the CJ-DATS Targeted intervention, a peer-based DVD intervention for risky drug and sexual behaviors for drug offenders about to reenter the community. After screening and obtaining consent, enrolled participants were given the intake questionnaire, randomized into intervention groups, and were offered HIV and HCV testing. Subjects tested for HIV and HCV received post-test counseling two weeks later. The study used a three-group randomized clinical trial to compare changes in risky behaviors in subjects receiving the CJ-DATS Targeted intervention with those receiving the NIDA standard intervention and the control group receiving "standard practice" post-release. Those assigned to the standard practice treatment attended a group session and were shown a video on HIV and Hepatitis awareness; those in the NIDA standard intervention received a HIV prevention session with a health educator using cue cards in a one-on-one setting; and those in the CJ-DATS Targeted intervention group were shown an interactive DVD in a peerfacilitated one-on-one setting. Follow-up interviews were conducted at 30 and 90 days postrelease. Subjects received $40 for participating in the baseline survey, $40 for the 30-day 17 follow up, and $60 for the 90-day follow up. Participation in all phases of the CJ-DATS study was voluntary. STUDY POPULATION AND ELIGIBILITY The CJ-DATS study dataset contained intake data from 672 eligible subjects recruited from two prisons in Kentucky, a halfway house in Delaware, and a local jail in Virginia between September 2006 and May 2008. All persons to be released from incarceration or work release to parole or probation at these participating sites during this time period were given an introduction to the CJ-DATS study and were shown a basic HIV education video. Those willing to participate in the study were screened within 30 days of being released and given informed consent forms to sign. Eligible participants were released offenders who met the TCU Drug Intake Screener criteria for substance abuse or dependence, were 18 years of age or older, and had given consent to participate. Released offenders who had an existing diagnosis of a DSM-IV-R psychotic disorder, had evidence of neuropsychological dysfunction, or had a life expectancy of less than 6 months were excluded from the CJ-DATS study. For this analysis, only participants who completed the intake survey and were tested for Hepatitis C were included. As the CJ-DATS dataset was made publicly available, personal identifiers such as participant date of birth and research site were removed and could not be included in this analysis. Participants with inconclusive HCV test results ('Unknown' or 'Pending') and missing data for sexual behavior and covariates were not included in this analysis. The final sample size for this analysis was 614 participants after removing those without a valid HCV result and those with missing data, as shown in Figure 1. DATA COLLECTION AND MEASURES Self-reported data from subjects was collected during an in-depth baseline interview using the HIV/HEPC intake survey. These interviews were conducted face-to-face and took place within 30 days of the participant's release from incarceration. The survey consisted of several components: 18 Figure 1. Final sample size for present analysis. 1. The CJ-DATS core questionnaire supplemented with Brief Symptoms Inventory (BSI) was used to collect baseline data on demographics, drug use, HIV/AIDs and related risk behaviors, and mental health measures. 2. The AIDS Health Belief Scale was added to assess perceived susceptibility to AIDS, perceived seriousness of AIDS, and perceived benefits and barriers to adopting safer behaviors. 3. The AIDS Risk Behavior Knowledge was added to measure AIDS knowledge. 4. The NIDA Risk Behavioral Assessment (RBA) and Revised RBA was included to collect baseline data related to HIV/AIDS and related risk behavior and health measures. The survey was modified to include questions related to HCV. Subjects were asked questions relating to their sociodemographic background, relationships with friends and family, criminal history, health and psychological status, substance abuse and treatment history, risk behaviors, HIV/HCV knowledge, and attitudes toward condom use. Survey questions asked at baseline referred to participants' activities before and during incarceration. HIV testing was done using the OraSure rapid oral test. HCV testing was done using Serum ELISA antibody assays to determine HCV seropositivity, the presence of antibody to Hepatitis C virus. The ELISA assay is the most widely used screening test for anti-HCV and can be used to screen large populations (Debois, 19 Vaghefi, Savary, Dussaix, & Roque-Afonso, 2008). Anti-HCV immunoassays indicate if a person has a current infection or was infected in the past, but cannot differentiate between acute, chronic, or resolved infection (CDC, 1998). Studies have estimated the thirdgeneration ELISA to have a sensitivity between 97.2% and over 99% and a specificity of 99% (Colin et al., 2001; Debois et al., 2008; Pawlotsky, 2002). The proportion of false positives with this immunoassay averages about 35% in immunocompetent populations and 15% in immunocompromised populations when the prevalence of anti-HCV is less than 10% (CDC, 2003b). It is recommended that a positive anti-HCV test be confirmed with a more specific serologic test, such as a recombinant immunoblot assay, or a nucleic acid test. STUDY VARIABLES Variables included in this study are described and listed below. The outcome and main variable of interest are detailed first, followed by demographic and other HCV risk behavior variables. Outcome and Main Variable of Interest The outcome variable for this analysis is the Hepatitis C test result (Negative or Positive). The main predictor for this analysis is reported sexual behavior in the 6 months prior to the arrest that resulted in their incarceration, gathered from responses to survey questions asking about the number of sexual partners and the frequency of unprotected sex with various partners. Participants were asked: 'How many different people did you have sex with during the last 6 months prior to the arrest date on the timeline?' 'During those months, how often did you have sex without using a condom with a casual partner?' ('Never', ' Only a few times','1-3 times a month','1-5 times a week', 'About every day') 'During those months, how often did you have sex without using a condom with an IDU?' ('Never', ' Only a few times','1-3 times a month','1-5 times a week', 'About every day') 'During those months, how often did you have sex without using a condom with either you or your partner exchanging sex for drugs, money, or gifts?' ('Never', ' Only a few times','1-3 times a month','1-5 times a week', 'About every day') For this analysis, these questions were combined and re-coded to create one sexual behavior variable based on their number of partners and whether they reported having unprotected sex 20 with a casual partner, an IDU, or while they or their partner exchanged sex. Participants were divided into the following categories: Participants reporting having no partners in the 6 months prior to their arrest Participants reporting having 1-3 partners and never having unprotected sex with a casual partner, an IDU, or while they or their partner exchanged sex in the 6 months prior to their arrest Participants reporting 4 or more partners and never having unprotected sex with a casual partner, an IDU, or while they or their partner exchanged sex in the 6 months prior to their arrest Participants reporting 1-3 partners and having unprotected sex with a casual partner, an IDU, or while they or their partner exchanged sex in the 6 months prior to their arrest Participants reporting 4 or more partners and having unprotected sex with a casual partner, an IDU, or while they or their partner exchanged sex in the 6 months prior to their arrest The following is a list of other variables included for this analysis: History of STIs Participants were asked if they had ever been told by a doctor, nurse, or health care worker that they had Genital Herpes ('Yes' or 'No'), Gonorrhea ('Yes' or 'No'), Syphilis ('Yes' or 'No'), or Chlamydia ('Yes' or 'No'). Participants reporting a history of at least one STI were considered as having a history of STIs. History of Injection Drug Use The CJ-DATS survey asked participants to give the age they started injecting for different drugs and how often in the 6 months prior to their arrest did they inject drugs. Participants were asked: How old were you the first time you injected: cocaine; heroin and cocaine; heroin and methamphetamine; heroin; methadone; other opiates; methamphetamine; librim/valium/minor tranquilizers; barbituates; other sedatives; non-prescription GHB; ketamine; other (Age, '0' for those who never injected) 'In the last 6 months prior to the arrest date, how often did you inject illegal drugs with a needle?' ('Never/Not used', 'Only 1-3 times', 'About 1 time per month', 'About 2-3 times per month', 'About 1 time per week', 'About 2-6 times per week', 'About 1 time per day', 'About 2-3 times per day', 'About 4 or more times per day') 21 For this analysis, these questions and participant responses were recoded to create one categorical variable for injection drug use. Participants with a '0' response given for age of first injection for all drugs and a 'Never/Not used' response for the frequency of injecting drugs in the 6 months prior to their arrest were considered as reporting no history of injection drug use; participants with at least one age response given for age of first injection for any drugs or reported injecting drugs with any frequency in the 6 months prior to their arrest were considered as reporting a history of injection drug use. Other HCV Risk Behaviors Participants were asked if they ever had a tattoo ('Yes' or 'No') and if they ever had a blood transfusion ('Yes' or 'No'). Total Years Incarcerated Participants were asked to give the total amount of time they had ever spent in jail, prison, or juvenile lock-up (Number of months). The total time incarcerated was then converted to number of years and divided into the following categories: less than 2 years, 2-5 years, and over 5 years. Sociodemographic Variables Age ('How old are you?'), race ('What race or ethnic background do you most identify?' 'African American/Black', 'Asian', 'Native American', 'Pacific Islander', 'White', 'Other'), and gender ('Female' or 'Male') were also be included as covariates for this analysis. Age was categorized into two groups: participants ages 18 to 40 and participants ages 41 and older. The age limits for this variable were based on CDC recommendations that those born during 1945-1965 be tested for Hepatitis C (CDC, 2012). STATISTICAL ANALYSIS All statistical analyses were performed using SAS Version 9.2 software. Descriptive statistics were run to give frequencies for each of the categorical covariates: sexual behaviors, history of STIs, history of injection drug use, age group, ever having a tattoo, ever having a blood transfusion, race, gender, and total years incarcerated. 22 To assess the relationship between sexual behaviors and positive HCV status, bivariate associations using chi-squared tests and simple logistic regression were performed to give crude odds ratios, 95% confidence intervals, and p-values. Significance was determined using p<0.05. Variables found to be significantly associated with sexual behavior and HCV test result in the bivariate analysis were assessed for confounding and effect modification. Potential confounders were assessed using the 10% rule of thumb, and were placed in a simple logistic model with only sexual behavior and HCV result. Variables that changed the odds ratio between sexual behavior and the outcome HCV status by 10% or more were considered to be confounders and included in the final multivariable model. Interactions between these covariates and the main variable of interest sexual behavior were tested in the multivariable analyses with significance at p<0.10. All variables, regardless of significance in the bivariate analysis, were included in the multivariable analyses. Backwards stepwise logistic regression was run to identify variables independently associated with a positive HCV result and obtain odds ratios and confidence intervals adjusting for all other variables in the model. Covariates significant at p<0.05 and confounders were kept in the final model. 23 CHAPTER 4 RESULTS A total of 672 participants were included in the CJ-DATS dataset. Of these participants, 43 had missing or invalid Hepatitis C test results and another 15 were missing data on key variables. A final sample size of 614 participants was analyzed for this thesis. Descriptive statistics on demographic variables and other covariates are listed in Table 1. There were 488 men (79%) and 126 women (21%) in this sample. The median age of participants was 34. There were 442 participants aged 18 to 40 (72%) and 172 participants aged 41 to 76 (28%). For race, 246 participants identified as White (40%) and 368 participants identified as Black (60%). There were no participants reporting any other options for race. The median total time incarcerated was 4 years, and almost 39% (n=237) of participants reported their total time incarcerated to be over 5 years. All study participants had a history of substance abuse, as defined by the TCU Drug Intake Screener criteria for substance abuse or dependence used to determine participant eligibility into the CJ-DATS study. History of injection drug use was reported by 147 participants (24%). Almost two-thirds (n=397) of the sample reported ever having a tattoo, and less than 10% of participants (n=51) reported ever having a blood transfusion. Regarding sexual behavior, over a third of participants (34%) reported having 4 or more partners in the 6 months prior to their arrest, and half of the sample (50%) reported having unprotected sex with a casual partner, an IDU, or while they or their partner exchanged sex. Over a fourth of participants (26%) reported having unprotected sex and 4 or more sexual partners. Just over one-fifth of the sample (22%) reported having a history of STIs. Almost one-fourth of the sample (23%) tested positive for Hepatitis C. Of the 11 participants that tested positive for HIV, 7 (64%) also tested positive for HCV. Regarding sexual behavior, almost 46% (n=11) of those reporting having 0 partners in the 6 months prior to arrest tested positive for HCV. The prevalence of HCV was lower in those reporting 1-3 partners and no unprotected sex (22%) compared to those reporting 1-3 partners and 24 Table 1. Descriptive Statistics for Covariates of Interest in Drug Offenders Recently Released from Incarceration, n=614 Total HCV Positive HCV Negative n (%) n (%) n (%) 614 (100%) 144 (23.4) 470 (76.6) Negative 602 (98.0) 137 (22.8) 465 (77.2) Positive 11 (1.8) 7 (63.6) 4 (36.4) Result Pending 1 (0.2) - - 24 (3.9) 11 (45.8) 13 (54.2) 232 (37.8) 50 (21.5) 182 (78.5) VARIABLES HCV test result a HIV test result Sexual behavior 0 partners 1-3 partners and no unprotected sex 4 or more partners and no unprotected sex 54 (8.8) 4 (7.4) 50 (92.6) 1-3 partners and unprotected sex 147 (24.0) 44 (29.9) 103 (70.1) 4 or more partners and unprotected sex 157 (25.6) 35 (22.3) 122 (77.7) No 479 (78.0) 112 (23.4) 367 (76.6) Yes 135 (22.0) 32 (23.7) 103 (76.3) No 467 (76.1) 48 (10.3) 419 (89.7) Yes 147 (23.9) 96 (65.3) 51 (34.7) No 217 (35.3) 43 (19.8) 174 (80.2) Yes 397 (64.7) 101 (25.4) 296 (74.6) No 563 (91.7) 128 (22.7) 435 (77.3) Yes 51 (8.3) 16 (31.4) 35 (68.6) 18 to 40 442 (72.0) 68 (15.4) 374 (84.6) 41 to 76 172 (28.0) 76 (44.2) 96 (55.8) Male 488 (79.5) 106 (21.7) 382 (78.3) Female 126 (20.5) 38 (30.2) 88 (69.8) White 246 (40.1) 84 (34.1) 162 (65.9) Black 368 (59.9) 60 (16.3) 308 (83.7) <2 166 (27.0) 32 (19.3) 134 (80.7) 2-5 211 (34.4) 40 (19.0) 171 (81.0) >5 237 (38.6) 72 (30.4) 165 (69.6) History of STIs History of injection drug use Tattoo Blood transfusion Age Sex Race Total time incarcerated (Years) a Outcome variable Hepatitis C test result coded Positive or Negative 25 unprotected sex (30%). This trend was also present in those reporting 4 or more partners: the prevalence of HCV was 7% for those reporting no unprotected sex and 22% for those reporting having unprotected sex. The prevalence of HCV in participants reporting a history of STIs was the same as those reporting no history of STIs (23%). Over 40% (n=76) of participants aged 41-76 tested positive for HCV, compared to 15% (n=68) of participants aged 18-40. Of those that reported a history of injection drug use, 65% (n=96) tested positive for HCV, compared to 10% (n=48) of those who reported no history of injection drug use. The prevalence of positive HCV result was higher among White participants (34%) than in Black participants (16%). HCV prevalence was also higher among women (30%) than in men (22%). Thirty percent of participants (n=72) who reported their total time incarcerated to be over 5 years were positive for HCV, compared to less than 20% of participants (n=32) who reported less than 2 years and less than 20% of participants (n=40) who reported between 2-5 years. The descriptive frequencies and chi-squared p-values for the associations between the covariates and sexual behavior are shown in Table 2. Variables found to be significantly associated with sexual behavior were having a positive HCV result, reporting a history of STIs, reporting a history of IDU, age group, race, and total years incarcerated. Comparing sexual behavior between those testing positive for HCV and those testing negative, the frequency of having 4 or more partners and no unprotected sex was lower among those who tested positive (3%, n=4) compared to those who tested negative (11%, n=50). There was also a higher percentage of having 1-3 partners and unprotected sex among those who tested positive (31%, n=44) compared to those who tested negative (22%, n=103). The frequency of reporting 4 or more partners and unprotected sex was higher among those who had a history of STIs (39%, n=52) compared to those who had no history of STIs (22%, n=105). Those with a history of STIs also had a lower percentage of having 1-3 partners and no unprotected sex (27%, n=36) compared to those reporting no history of STIs (41%, n=196). Those with a history of IDU reported a lower frequency of having 1-3 partners and no unprotected sex (29%, n=43) compared to those with no history of IDU (41%, n=189). Those with a history of IDU also reported a lower percentage of having 4 or more partners and no unprotected sex (3%, n=4) compared to those with no history of IDU (11%, n=50). Those with a history of 26 Table 2. Descriptive and Bivariate Statistics for Covariates of Interest in Drug Offenders Recently Released from Incarceration, by Sexual Behavior Category, n=614 1-3 partners 0 partners >4 partners 1-3 partners >4 partners and no and no and and unprotected unprotected unprotected unprotected sex sex sex sex n (%) n (%) n (%) n (%) n (%) Negative 13 (2.8) 182 (38.7) 50 (10.6) 103 (21.9) 122 (26.0) Positive 11 (7.6) 50 (34.7) 4 (2.8) 44 (30.6) 35 (24.3) VARIABLES HCV test result a P-value 0.001 0.0004 History of STIs No 22 (4.6) 196 (40.9) 44 (9.2) 112 (23.4) 105 (21.9) Yes 2 (1.5) 36 (26.7) 10 (7.4) 35 (25.9) 52 (38.5) <0.0001 History of IDU No 16 (3.4) 189 (40.5) 50 (10.7) 95 (20.3) 117 (25.1) Yes 8 (5.4) 43 (29.3) 4 (2.7) 52 (35.4) 40 (27.2) 0.39 Tattoo No 12 (5.5) 86 (39.6) 19 (8.8) 52 (24.0) 48 (22.1) Yes 12 (3.0) 146 (36.8) 35 (8.8) 95 (23.9) 109 (27.5) 0.42 Blood transfusion No 20 (3.5) 215 (38.2) 51 (9.1) 136 (24.2) 141 (25.0) Yes 4 (7.8) 17 (33.3) 3 (5.8) 11 (21.6) 16 (31.4) 18 to 40 9 (2.0) 166 (37.6) 46 (10.4) 102 (23.1) 119 (26.9) 41 to 76 15 (8.7) 66 (38.4) 8 (4.7) 45 (26.2) 38 (22.1) Male 20 (4.1) 184 (37.7) 47 (9.6) 111 (22.8) 126 (25.8) Female 4 (3.2) 48 (38.1) 7 (5.6) 36 (28.6) 31 (24.6) White 11 (4.5) 101 (41.1) 12 (4.9) 73 (29.7) 49 (19.9) Black 13 (3.5) 131 (35.6) 42 (11.4) 74 (20.1) 108 (29.4) 0.0004 Age 0.46 Sex 0.0007 Race 0.03 Total years incarcerated a <2 5 (3.0) 68 (41.0) 13 (7.8) 50 (30.1) 30 (18.1) 2-5 10 (4.7) 82 (38.9) 20 (9.5) 51 (24.2) 48 (22.7) >5 9 (3.8) 82 (34.6) 21 (8.9) 46 (19.4) 79 (33.3) Outcome variable Hepatitis C test result coded Positive or Negative IDU had a higher percentage of having 1-3 partners and unprotected sex (35%, n=52) compared to those with no history of IDU (20%, n=95). Participants age 41-76 reported a higher percentage of having 0 partners (9%, n=15) than those age 18-40 (2%, n=9). Participants age 41-76 also had a lower percentage of having 4 or more partners and no 27 unprotected sex (5%, n=8) than those age 18-40 (10%, n=46). Black participants reported a lower percentage of having 1-3 partners and unprotected sex (20%, n=74) compared to White participants (30%, n=73). However, Black participants reported a higher percentage of having 4 or more partners and unprotected sex (29%, n=108) compared to White participants (20%, n=49). Comparing sexual behavior between those incarcerated less than 2 years, 2-5 years, and over 5 years, those incarcerated for less than 2 years reported the highest percentage for having 1-3 partners and unprotected sex (30%, n=50) and the lowest percentage for 4 or more partners and unprotected sex (18%, n=30); those incarcerated for more than 5 years reported the lowest percentage for having 1-3 partners and unprotected sex (19%, n=46) and the highest percentage for 4 or more partners and unprotected sex (33%, n=79). The unadjusted odds ratios, confidence intervals, and p-values for the bivariate associations between the independent variables and HCV test result are shown in Table 3. Sexual behavior, history of injection drug use, age group, race, and total years incarcerated were significantly associated with HCV result. Without adjusting for other variables, participants reporting 1-3 partners and no unprotected sex with a casual partner, IDU, or while they or their partner exchanged sex in the 6 months prior to arrest, were less likely (OR 0.3, 95% CI 0.1-0.8) to test positive for HCV than those reporting 0 partners. Participants reporting 4 or more partners and no unprotected sex were less likely (OR 0.1, 95% CI 0.030.4) to test positive for HCV than those reporting 0 partners. Participants reporting 4 or more partners and unprotected sex with a casual partner, IDU, or while they or their partner exchanged sex, were less likely (OR 0.3, 95% CI 0.1-0.8) to test positive for HCV than those reporting 0 partners. Without adjusting for other variables, participants reporting a history of injection drug use were more likely (OR 16.4, 95% CI 10.5-25.8) to test positive for HCV than those reporting no injection drug use. Participants ages 41 to 76 were more likely (OR 4.4, 95% CI 2.9-6.5) to test positive for HCV than those ages 18 to 40. Black participants were less likely (OR 0.4, 95% CI 0.3-0.6) to have a HCV positive test than White participants. Participants with over 5 total years incarcerated were more likely (OR 1.8, 95% CI 1.1-2.9) to have a positive HCV test than those incarcerated less than two years. And women were more likely 28 Table 3. Simple Logistic Regression of Covariates of Interest with Hepatitis C Test Result a for Drug Offenders Recently Released from Incarceration, n=614 VARIABLES Crude Odds Ratio 95% Confidence Interval P-value 0.002 Sexual behavior 0 partners 1.0* - 1-3 partners and no unprotected sex 0.3 (0.1, 0.8) 0.1 (0.03, 0.4) 0.5 (0.2, 1.2) 0.3 (0.1, 0.8) vs 0 partners 4 or more partners and no unprotected sex vs 0 partners 1-3 partners and unprotected sex vs 0 partners 4 or more partners and unprotected sex vs 0 partners <0.0001 History of injection drug use No 1.0* Yes 16.4 (10.5, 25.8) 0.12 Tattoo No 1.0* Yes 1.4 (0.9, 2.1) 0.17 Blood transfusion No 1.0* Yes 1.5 (0.8, 2.9) 0.94 History of STI No 1.0* Yes 1.0 18 to 40 1.0* 41 to 76 4.4 (0.6, 1.6) <0.0001 Age (2.9, 6.5) 0.05 Sex Male 1.0* Female 1.6 White 1.0* Black 0.4 (1.0, 2.4) <0.0001 Race (0.3, 0.6) 0.006 Total time incarcerated (Years) a <2 1.0* 2-5 1.0 (0.6, 1.6) >5 1.8 (1.1, 2.9) Outcome variable Hepatitis C test result coded Positive or Negative * Indicates reference group for categorical variables 29 (OR 1.6, 95% CI 1.0-2.4) to have a HCV positive test than men, but this association was borderline significant (p=0.05). Table 4 shows the results of the final multivariable logistic regression model with adjusted odds ratios for variables associated with HCV test result. History of injection drug use, age group, race, and total years incarcerated were found to be confounders in the association between sexual behavior and HCV test result and were kept in the final model. Interactions between these covariates and sexual behavior were tested at p<0.10 and none were found to be significant. A Hosmer and Lemeshow Goodness-of Fit Test was performed and confirmed the goodness of fit of this model (p=0.86). Adjusting for all other variables, sexual behavior was not significantly associated with HCV result (p=0.42). History of injection drug use and age group had significant independent associations with HCV test result. Adjusting for all other variables in the model, participants who reported injection drug use were more likely (OR 15.5, 95% CI 9.0-26.7) to have a positive HCV test than participants who reported no injection drug use. Participants ages 41-76 were more likely (OR 4.1, 95% CI 2.5-6.7) to have a positive HCV test result than participants ages 18-40. 30 Table 4. Final Multivariable Logistic Regression Model of Variables of Interest with Hepatitis C Test Result a for Drug Offenders Recently Released from Incarceration, n=614 VARIABLES Adjusted Odds 95% Confidence Interval P-value Ratio 0.42 Sexual behavior 0 partners 1.0* - 1-3 partners and no unprotected sex 0.5 (0.2, 1.5) 0.2 (0.05, 1.1) 0.5 (0.1, 1.5) 0.4 (0.1, 1.3) vs 0 partners 4 or more partners and no unprotected sex vs 0 partners 1-3 partners and unprotected sex vs 0 partners 4 or more partners and unprotected sex vs 0 partners <0.0001 History of injection drug use No 1.0* - Yes 15.5 (9.0, 26.7) 18 to 40 1.0* - 41 to 76 4.1 (2.5, 6.7) White 1.0* - Black 0.8 (0.5, 1.4) <0.0001 Age 0.43 Race 0.13 Total time incarcerated (Years) a <2 1.0* - 2-5 0.7 (0.4, 1.3) >5 1.2 (0.7, 2.2) Outcome variable Hepatitis C test result coded Positive or Negative * Indicates reference group for categorical variables 31 CHAPTER 5 DISCUSSION This chapter will discuss the key findings of this analysis, how these results compare to those found in other studies, and the public health implications of these results. The limitations and strengths of this thesis and directions for future research will also be discussed. KEY FINDINGS The current study examined the association between positive HCV test result and risky sexual behaviors in a sample of drug users recently released from incarceration. Almost a fourth of participants tested positive for HCV. Risky sexual behaviors were common in this sample with almost 50% reporting having unprotected sex with a casual partner, IDU, or while they or their partner exchanged sex, over 30% reporting having 4 or more partners, and 25% reporting having unprotected sex and 4 or more partners. Surprisingly, the prevalence of positive HCV status was highest in those reporting having 0 partners in the 6 months prior to arrest. The direction of the association between sexual behavior and HCV result in the bivariate analysis was also unexpected; participants reporting 1-3 partners and no unprotected sex, 4 or more partners and no unprotected sex, and 4 or more partners and unprotected sex with a casual partner, IDU, or while they or their partner exchanged sex, were less likely to have a positive HCV test than those reporting 0 partners. Although sexual behavior was only found to be significantly associated with HCV test result in the bivariate analysis, the association was not significant after adjusting for history of injection drug use and age group. These findings do not support the hypothesis that participants reporting risky sexual behaviors were more likely to have tested positive for HCV, compared to those who reported no risky sexual behaviors. In this study, there was no evidence of a significant association between sexual behavior and HCV test result in drug users recently released from incarceration after adjusting for other HCV risk variables. 32 Other studies in drug-using populations have found similar results regarding the association between sexual behaviors and HCV. A study in New York City asked 722 noninjecting drug users if they had IDU sex partners, sex partners with hepatitis, or had traded sex in the past 2 months (Howe et al., 2005). Although the bivariate analyses of the New York study suggested sex with a partner with hepatitis was associated with HCV, this association was not significant after adjusting for age. A study of 178 men recently released from incarceration found no significant associations between reporting unprotected vaginal or anal sex with multiple partners and HCV infection (Sosman et al., 2011). And, in a study of 1003 injection drug users conducted in New Mexico from 1995-1997, the seroprevalence of HCV was found to be highest in participants reporting 0 partners (91%), and the prevalence decreased in those reporting 1 (88%), 2 (86%), 3-4 (78%), and 5-9 sexual partners (67%) (Samuel et al., 2001). However, in those reporting 10-49 and 50+ sexual partners, the prevalence of HCV increased (68% and 83%, respectively). Although high rates of risky sexual behavior have been found among drug users, other factors relating to drug use, drug addiction, and previous incarceration may play a role in this trend. Different drugs may have different effects on sexual desire and behavior, and these effects may be influenced by duration of drug use, mental state, setting, and variation between individuals. For example, while cocaine has been reported by some studies to prolong arousal and delay or produce spontaneous orgasm, other research has shown chronic cocaine use to reduce sexual desire and ability and increase the difficulty of achieving orgasm (Rawson, Washton, Domier, & Reiber, 2002). Sexual behavior may also affect drug use behaviors. A prospective study of IDUs conducted over 10 years found that male IDUs who reported having no heterosexual partners were more likely to become infected with HIV, and this finding was not explained by homosexual or bisexual activity (Strathdee et al., 2001). Not having a partner who can provide social support may be associated with high-risk injection practices and could also be a marker of severe drug dependence. However, there may be an association between sexual behavior and HCV among incarcerated women. One study among 469 prisoners entering California State correctional facilities found that the odds of HCV infection for women reporting having sex with an IDU were more than 4 times higher than for women reporting not having sex with an IDU (Fox et al., 2005). A study of 542 incoming inmates from a jail in Northern Virginia also found that 33 in the 6 months before incarceration, women were more likely than men to report having unprotected sex with an IDU, ever using injection drugs, and using dirty needles (Adams et al., 2011). In regards to this sexual partnership, women may be initiated into injection drug use, increase the frequency of injection drug use, and share needles to build and maintain trust with male partners, increasing their risk of acquiring HCV (Evans et al., 2003). Female inmates may also be more likely than male inmates to be incarcerated for prostitution, injection drug use, crack/cocaine use, and other behaviors associated with an increased HCV risk (Baillargeon et al., 2003). The current study also found age and history of injection drug use to be independent correlates for HCV seropositivity, and the prevalence of HCV to be higher among participants who were White, female participants, and participants with higher cumulative years incarcerated. These findings are consistent with those from other studies of HCV in incarcerated populations. The relationship between increased age and increased HCV prevalence in incarcerated and drug-using populations has been attributed to higher cumulative exposure to HCV through the use of injection drugs over a longer period of time (Solomon, Flynn, Muck, & Vertefeuille, 2004). Lower HCV prevalence among Blacks in this population may be explained by a decreased frequency of injection drug use among this racial group than among Whites and other racial groups. A study by Khan et al. (2012) found that among young adults, Blacks were much less likely to report non-injection crack-cocaine and injection drug use compared to Whites, Latinos, Native Americans, and Asian Americans. A study by Broz and Ouellet (2008) found that admissions to publicly-funded drug treatment programs between 1992 and 2004 among White IDUs increased, whereas admissions among Black IDUs declined, and there was a substantial decline in young Black heroin IDUs enrolling in research studies. Among IDU-related acute hepatitis C cases reported to 6 U.S. county health departments from 1982 to 2006, the lowest proportion of cases was reported by Blacks (28%) compared to Whites (34%) and Hispanics (40%) (Williams, Bell, Kuhnert, & Alter, 2011). LIMITATIONS This study had several limitations that should be considered in interpreting its findings. The eligibility criteria to participate in the NIDA CJ-DATS study excluded those 34 with an existing and diagnosed DSM-IV-R psychotic disorder, leaving out an important atrisk group for HCV. The prevalence of HCV is higher among people with severe mental illness compared to the general population, and people with severe mental illness are likely to engage in risky behaviors that put them at risk for blood-borne infections such as HIV, HBV, and HCV(Rosenberg et al., 2001). People with severe mental illness are likely to engage in high-risk behaviors such as having multiple sexual partners and high-risk partners, infrequent condom use, same-sex sexual activity, trading sex for money or drugs, engaging in sex while using psychoactive substances, and injecting drugs. Severe mental illness is more prevalent in incarcerated populations than in the general population; results from the Survey of Inmates in State and Federal Correctional Facilities, 2004, and the Survey of Inmates in Local Jails, 2002, found that 15% of State prisoners, 10% of Federal prisoners, and 24% of jail inmates had a psychotic disorder, compared to 3% of adults in the U.S. general population (James & Glaze, 2006). Fifty percent of adults in the U.S. with severe mental illness are 'dually diagnosed' with co-occurring substance abuse disorders, elevating their risk for HCV (Rosenberg et al., 2005). Mental problems have also been linked to substance abuse in incarcerated populations; 74% of State prisoners and 76% of local jail inmates with a mental health problem also met criteria for substance dependence or abuse (James & Glaze, 2006). Survey administration was done using interviews, which could have resulted in nonresponse bias or social desirability bias if participants declined to report or underreported risk behaviors. Recall bias may have occurred as it may have been difficult for participants at the end of their incarceration to remember their sexual behaviors in the 6 months before they were arrested. Misclassification bias may have occurred if participants failed to report or underreported sexual behaviors they engaged in during those 6 months. Misclassification of those who were infected with HCV may have also occurred if the HCV antibody test was administered during the "window period" of 1-3 weeks after infection during which the test would not be able to detect HCV antibodies in the blood. Positive HCV tests were not followed up with confirmatory tests, so the occurrence of false positives, although rare in populations with HCV prevalence over 10%, is possible. Although HIV is an important risk factor for HCV infection, this variable was not included in the analysis beyond descriptive statistics due to the small number of HIVinfected participants (n=11). As this analysis used an existing data set, questions on risky 35 sexual behaviors were limited. Information collected for participants' sexual behavior was limited only to the period of 6 months before their arrest that resulted in their incarceration; information regarding participants' sexual behaviors during their incarceration was not collected. As participants were tested for HCV within 30 days of being released from incarceration, sexual behaviors occurring during incarceration or after release that may have played a role in HCV transmission were unaccounted for in this analysis. No data was collected on sexual behaviors with increased trauma and blood-to-blood contact, such as anal sex and rape, during the 6 months before arrest. The study data also did not have available information on which sites participants were recruited from, so differences in the association between sexual behavior and HCV test result between the sites could not be assessed. And as this secondary analysis was a cross-sectional study, causality and temporality between sexual behavior and HCV could not be assessed. STRENGTHS Because this study was restricted to drug users and injection drug use is a significant risk factor for HCV, it is important to correctly classify those who have ever injected drugs from those who have never injected drugs to assess the association between sexual behavior and HCV status. To reduce misclassification of participants who ever injected drugs and those who never injected drugs, participant responses to two survey questions asking about age of first injection drug use of any drug and frequency of injecting drugs in the 6 months before arrest were combined to determine whether or not participants ever injected drugs. HCV status was assessed using a HCV ELISA antibody test rather than through self-report. The HCV ELISA antibody test is highly sensitive and specific and rarely produces false positives when the prevalence in the population in which it is administered is greater than 10% (CDC, 2003b). A large sample size of 614 allowed for a multivariate analysis. IMPLICATIONS AND FUTURE RESEARCH Age and injection drug use are known risk factors for HCV and were found to be significantly associated with positive HCV result in this study. Screening those born during 1945-1965 and injection drug users upon entry into correctional settings represents an opportunity to detect and treat undiagnosed cases and prevent transmission to others. In 36 situations where screenings are not implemented due to incarcerated persons having shorter sentences than the length of HCV therapy, prisons and jails can provide links to community health clinics to prevent interruption of care and increase completion of treatment when persons being treated for HCV are released from incarceration. Offering substance abuse treatment to drug users would also reduce the risk of HCV transmission through injection drug use, as well as prevent recidivism from drug-related offenses. Substance abuse programs in correctional facilities and in communities could collaborate to provide counseling and treatment to individuals when they are incarcerated and after they are released to prevent relapsing into substance abuse. Needle-exchange programs in communities can help reduce the risk of acquiring and transmitting HCV and HIV in IDUs who are released from incarceration and continue to use drugs. This study also found that risky sexual behaviors were common in this population. Incarcerated populations would benefit from STI screening upon entry, in-house sexual health education on preventing HIV, STIs, and hepatitis, and referral to community STI clinics and sexual health services upon release. Incarcerated persons may also benefit from provision of condoms and other safe sex supplies such as lube and dental dams within correctional facilities. Although this intervention is controversial due to concerns about adverse consequences, including that access to condoms might be seen as allowing and condoning sexual activity or that condoms could be used to conceal drugs, research has not found access to condoms to constitute a threat to security or operations, and condom access has not been found to result in increased sexual activity (World Health Organization, 2007). Correctional facilities should also have strategies in place to enhance detection, prevention, and reduction of sexual violence. Such strategies include ways of documenting and reporting sexual assault, inmate and staff education, staff training, and counseling and post-exposure prophylaxis treatment for victims. Prevention services in correctional facilities and linkages to community health services are needed to screen and treat undiagnosed cases, educate and counsel at-risk groups, and prevent transmission among marginalized population with high disease burdens and high rates of risk behaviors. Having integrated substance abuse treatment and sexual health education available during incarceration and after release are essential to prevent and control diseases that can be spread through risky drug use and sexual behaviors in a population that engages in high rates of both. 37 Future research should investigate the causal relationship between sexual behaviors and hepatitis C in incarcerated populations. To examine this relationship in correctional settings, prospective studies are needed to determine whether engaging in risky sexual behavior while incarcerated increases the risk of HCV. Research on this relationship should also include incarcerated persons with mental illness as mental health issues are prevalent in incarcerated populations and those with severe mental illness are at increased risk for HCV and are more likely to engage in risky sexual and drug behaviors. It would also be interesting to examine the differences in risky sexual behaviors between IDUs, NIDUs, and users of different types of drugs, and what factors are driving these differences. 38 REFERENCES Adams, L., Kendall, K., Smith, A., Quigley, E., Stuewig, J., & Tangney, J. (2011). HIV risk behaviors of male and female jail inmates prior to incarceration and one year postrelease. AIDS Behavior, 1-10. Amon, J., Garfein, R., Ahdieh-Grant, L., Armstrong, G., Ouellet, L., Latka, M., . . . William, I. (2008). Prevalence of Hepatitis C virus infection among injection drug users in the United States, 1994--2004. Clinical Infectious Diseases, 46(12), 1852-1858. Awofeso, N. (2010). Prisons as social determinants of Hepatitis C virus and tuberculosis infections. Public Health Reports, 125(Suppl 4), 25-33. Baillargeon, J., Wu, H., Kelley, M., Grady, J., Linthicum, L., & Dunn, K. (2003). Hepatitis C seroprevalence among newly incarcerated inmates in the Texas correctional system. Public Health, 117(1), 43-48. Bauserman, R., Richardson, D., Ward, M., Shea, M., Bowlin, C., Tomoyasu, N., & Solomon, L. (2003). HIV prevention with jail and prison inmates: Maryland's Prevention Case Management program. AIDS Education and Prevention, 15(5), 465-480. Beck, A., & Harrison, P. (2008). Sexual victimization in local jails reported by inmates, 2007. US Department of Justice, Office of Justice Programs, Bureau of Justice Statistics. Retrieved from http://www.bjs.gov/index.cfm?ty=pbdetail&iid=1148 Beck, A., & Maruschak, L. (2004). Hepatitis testing and treatment in state prisons. United States Department of Labor, Office of Justice Programs. Retrieved from http://bjs.gov/content/pub/pdf/httsp.pdf Binswanger, I., Krueger, P., & Steiner, J. (2009). Prevalence of chronic medical conditions among jail and prison inmates in the USA compared with the general population. Journal of Epidemiology and Community Health, 63(11), 912-919. Broz, D., & Ouellet, L. (2008). Racial and ethnic changes in heroin injection in the United States: Implications for the HIV/AIDS epidemic. Drug and Alcohol Dependence, 94(1-3), 221-233. Burton, M., Reilly, K., & Penman, A. (2010). Incarceration as a risk factor for Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) co-infection in Mississippi. Journal of Health Care for the Poor and Underserved, 21(4), 1194-1202. Carson, A., & Sabol, W. (2012). Prisoners in 2011. US Department of Justice, Office of Justice Programs, Bureau of Justice Statistics. Retrieved from http://www.bjs.gov/index.cfm?ty=pbdetail&iid=4559 Centers for Disease Control and Prevention (CDC). (1998). Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Morbidity and Mortality Weekly Report, 47, 1-33. 39 Centers for Disease Control and Prevention (CDC). (2003a). Prevention and control of infections with Hepatitis Viruses in correctional settings. Morbidity and Mortality Weekly Report, 52, 1-33. Centers for Disease Control and Prevention (CDC). (2003b). Guidelines for laboratory testing and result reporting of antibody to Hepatitis C Virus. Morbidity and Mortality Weekly Report, 52, 1-16. Centers for Disease Control and Prevention (CDC). (2010). Sexually transmitted disease treatment guidelines, 2010. Morbidity and Mortality Weekly Report, 59(RR-12). Centers for Disease Control and Prevention (CDC). (2011a). Hepatitis C information for health professionals. Retrieved from http://www.cdc.gov/Hepatitis/HCV/index.htm Centers for Disease Control and Prevention (CDC). (2011b). Hepatitis C and incarceration. United States Department of Health and Human Services Publication No.21-1306. Retrieved from http://www.cdc.gov/Hepatitis/Settings/Corrections.htm Centers for Disease Control and Prevention (CDC). (2012). Recommendations for the identification of chronic Hepatitis C Virus Infection among persons born during 1945-1965. Morbidity and Mortality Weekly Report, 61(4), 1-18. Chak, E., Talal, A., Sherman, K., Schiff, E., & Saab, S. (2011). Hepatitis C virus infection in USA: An estimate of true prevalence. Liver International, 31(8), 1091-1101. Chandler, R., Fletcher, B., & Volkow, N. (2009). Treating drug abuse and addiction in the criminal justice system. JAMA: The Journal of the American Medical Association, 301(2), 183-190. Colin, C., Lanoir, D., Touzet, S., Meyaud-Kraemer, L., Bailly, F., & Trepo, C. (2001). Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: An analysis of the literature. Journal of Viral Hepatitis, 8(2), 87-95. Collica, K. (2007). The prevalence of HIV peer programming in American prisons: An opportunity wasted. Journal of Correctional Health Care, 13(4), 278-288. Danta, M., Brown, D., Bhagani, S., Pybus, O., Sabin, C., Nelson, M., . . . Dusheiko, G. (2007). Recent epidemic of acute Hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS, 21(8), 983-991. Desbois, D., Vaghefi, P., Savary, J., Dussaix, E., & Roque-Afonso, A. (2008). Sensitivity of a rapid immuno-chromatographic test for hepatitis C antibodies detection. Journal of Clinical Virology, 41(2), 129-133. Evans, J., Hahn, J., Page-Shafer, K., Lum, P., Stein, E., Davidson, P., & Moss, A. (2003). Gender differences in sexual and injection risk behavior among active young injection drug users in San Francisco (the UFO Study). Journal of Urban Health, 80(1), 137-146. Fox, R., Currie, S., Evans, J., Wright, T., Tobler, L., Phelps, B., . . . Page-Shafer, K. (2005). Hepatitis C virus infection among prisoners in the California state correctional system. Clinical Infectious Diseases, 41(2), 177-186. 40 Freudenberg, N. (2001). Jails, prisons, and the health of urban populations: A review of the impact of the correctional system on community health. Journal of Urban Health, 78(2), 214-235. Ghany, M., Strader, D., Thomas, D., & Seeff, L. (2009). Diagnosis, management, and treatment of Hepatitis C: An update. Hepatology, 49(4), 1335-1374. Ghosn, J., Thibault, V., Delaugerre, C., Fontaine, H., Lortholary, O., Rouzioux, C., . . . Chaix, M. (2008). Sexually transmitted Hepatitis C virus superinfection in HIV/Hepatitis C virus co-infected men who have sex with men. AIDS, 22(5), 658-661. Glaze, L., & Parks, E. (2012). Correctional populations in the United States, 2011. US Department of Justice, Office of Justice Programs, Bureau of Justice Statistics. Retrieved from http://www.bjs.gov/index.cfm?ty=pbdetail&iid=4537 Hagan, H., Thiede, H., & Des Jarlais, D. (2005). HIV/Hepatitis C virus co-infection in drug users: Risk behavior and prevention. AIDS, 19(Suppl 3), 199-207. Hahn, J. (2007). Sex, drugs, and Hepatitis C virus. Journal of Infectious Diseases, 195(11), 1556-1559. Hahn, J., Page-Shafer, K., Lum, P., Bourgois, P., Stein, E., Evans, J., . . . Moss, A. (2002). Hepatitis C virus seroconversion among young injection drug users: Relationships and risks. Journal of Infectious Diseases, 186(11), 1558-1564. Harzke, A., Baillargeon, J., Kelley, M., Diamond, P., Goodman, K., & Paar, D. (2009). HCV-related mortality among male prison inmates in Texas, 1994-2003. Annals of Epidemiology, 19(8), 582-589. Howe, C., Fuller, C., Ompad, D., Galea, S., Koblin, B., Thomas, D., & Vlahov, D. (2005). Association of sex, hygiene and drug equipment sharing with Hepatitis C virus infection among non-injecting drug users in New York City. Drug and Alcohol Dependence, 79(3), 389-395. Inciardi, James A. (2011). Criminal Justice Drug Abuse Treatment Studies (CJ-DATS): HIV/HEPATITIS prevention for re-entering drug offenders. ICPSR29061-v1. doi:10.3886/ICPSR29061.v1 James, D., & Glaze, E. (2006). Mental health problems of prison and jail inmates. United States Department of Justice, Office of Justice Programs, Bureau of Justice Statistics. Retrieved from http://bjs.gov/content/pub/pdf/mhppji.pdf Khan, M., Berger, A., Hemberg, J., O’Neill, A., Dyer, T., & Smyrk, K. (2012). Non-injection and injection drug use and STI/HIV risk in the United States: The degree to which sexual risk behaviors versus sex with an STI-infected partner account for infection transmission among drug users. AIDS and Behavior, 17(3), 1-10. Klein, S., Wright, L., Birkhead, G., Mojica, B., Klopf, L., Klein, L., . . . Fraley, E. (2007). Promoting HCV treatment completion for prison inmates: New York state's Hepatitis C continuity program. Public Health Reports, 122(Suppl 2), 83-88. 41 Lavanchy, D. (2011). Evolving epidemiology of Hepatitis C virus. Clinical Microbiology and Infection, 17(2), 107-115. Macalino, G., Vlahov, D., Sanford-Colby, S., Patel, S., Sabin, K., Salas, C., & Rich, J. (2004). Prevalence and incidence of HIV, Hepatitis B virus, and Hepatitis C virus infections among males in Rhode Island prisons. Journal Information, 94(7), 12181223. Mackesy-Amiti, M., Boodram, B., Williams, C., Ouellet, L., & Broz, D. (2012). Sexual risk behavior associated with transition to injection among young non-injecting heroin users. AIDS and Behavior. Advance online publication. doi: 10.1007/s10461-0120335-6 Maru, D., Bruce, R., Basu, S., & Altice, F. (2008). Clinical outcomes of Hepatitis C treatment in a prison setting: Feasibility and effectiveness for challenging treatment populations. Clinical Infectious Diseases, 47(7), 952-961. Minton, T. (2011). Jail inmates at midyear 2010-Statistical tables. Bureau of Justice Statistics. Retrieved from http://bjs.gov/content/pub/pdf/jim10st.pdf Morrow, K., & the Project START Study Group. (2009). HIV, STD, and Hepatitis risk behaviors of young men before and after incarceration. AIDS Care , 21(2), 235-243. Mumola, C., & Karberg, J. (2006). Drug use and dependence, state and federal prisoners, 2004. United States Department of Justice, Office of Justice Programs, Bureau of Justice Statistics. Retrieved from http://bjs.gov/content/pub/pdf/dudsfp04.pdf Neumayr, G., Propst, A., Schwaighofer, H., Judmaier, G., & Vogel, W. (1999). Lack of evidence for the heterosexual transmission of Hepatitis C. Q Journal of Medicine, 92(9), 505-508. Pawlotsky, J. (2002). Use and interpretation of virological tests for Hepatitis C. Hepatology, 36(Suppl 1), 65-73. Rawson, R., Washton, A., Domier, C., & Reiber, C. (2002). Drugs and sexual effects: Role of drug type and gender. Journal of Substance Abuse Treatment, 22, 103-108. Rich, Josiah D., Wakeman, Sarah E., & Dickman, Samuel L. (2011). Medicine and the epidemic of incarceration in the United States. The New England Journal of Medicine, 364(22), 2081-2083. Rosenberg, S., Goodman, L., Osher, F., Swartz, M., Essock, S., Butterfield, M., . . . Salyers, M. (2001). Prevalence of HIV, Hepatitis B, and Hepatitis C in people with severe mental illness. American Journal of Public Health, 91(1), 31-37. Rosenberg, Stanley D., Drake, Robert E., Brunette, Mary F., Wolford, George L., & Marsh, Bryan J. (2005). Hepatitis C virus and HIV co-infection in people with severe mental illness and substance use disorders. AIDS, 19(Suppl 3), 26-33. Ross, Michael W., Hwang, L-Y., Zack, C., Bull, L., & Williams, M. (2002). Sexual risk behaviours and STIs in drug abuse treatment populations whose drug of choice is crack cocaine. International Journal of STD & AIDS, 13, 769-774. 42 Samuel, M., Doherty, P., Bulterys, M., & Jenison, S. (2001). Association between heroin use, needle sharing and tattoos received in prison with Hepatitis B and C positivity among street-recruited injecting drug users in New Mexico, USA. Epidemiology and Infection, 127(3), 475-484. Shepard, C., Finelli, L., & Alter, M. (2005). Global epidemiology of Hepatitis C virus infection. The Lancet Infectious Diseases, 5(9), 558-567. Sherman, S., & Latkin, C. (2001). Intimate relationship characteristics associated with condom use among drug users and their sex partners: A multilevel analysis. Drug and Alcohol Dependence, 64(1), 97-104. Sieck, C., & Dembe, A. (2011). Results of a pilot study of pre-release STD testing and inmates’ risk behaviors in an Ohio prison. Journal of Urban Health, 88(4), 690-699. Solomon, L., Flynn, C., Muck, K., & Vertefeuille, J. (2004). Prevalence of HIV, syphilis, Hepatitis B, and Hepatitis C among entrants to Maryland correctional facilities. Journal of Urban Health, 81(1), 25-37. Somlai, A., Kelly, J., McAuliffe, T., Ksobiech, K., & Hackl, K. (2003). Predictors of HIV sexual risk behaviors in a community sample of injection drug-using men and women. AIDS and Behavior, 7(4), 383-393. Sosman, J., MacGowan, R., Margolis, A., Gaydos, C., Eldridge, G., Moss, S., . . . Belcher, L. (2011). Sexually transmitted infections and Hepatitis in men with a history of incarceration. Sexually Transmitted Diseases, 38(7), 634-639. Spaulding, A., & Thomas, D. (2012). Screening for HCV infection in jails. JAMA: The Journal of the American Medical Association, 307(12), 1259-1260. Spaulding, A., Weinbaum, C., Lau, D., Sterling, R., Seeff, L., Margolis, H., & Hoofnagle, J. (2006). A framework for management of Hepatitis C in prisons. Annals of Internal Medicine, 144(10), 762-769. Stephan, J. (2008). Census of state and federal correctional facilities, 2005. United States Department of Justice, Office of Justice Programs, Bureau of Justice Statistics. Retrieved from http://www.bjs.gov/content/pub/pdf/csfcf05.pdf Strader, D. (2005). Coinfection with HIV and Hepatitis C virus in injection drug users and minority populations. Clinical Infectious Diseases, 41(Suppl 1), 7-13. Strathdee, S., Galai, N., Safaiean, M., Celentano, D., Vlahov, D., Johnson, L., & Nelson, K. (2001). Sex differences in risk factors for HIV seroconversion among injection drug users: A 10-year perspective. Archives of Internal Medicine, 161, 1281-1288. Tan, J., Joseph, T., & Saab, S. (2008). Treating Hepatitis C in the prison population is costsaving. Hepatology, 48(5), 1387-1395. Terrault, N., Dodge, J., Murphy, E., Tavis, J., Kiss, A., Levin, T., . . . Alter, M. (2013). Sexual transmission of HCV among monogamous heterosexual couples: The HCV partners study. Hepatology, 57(3), 881-889. Thomas, D., Cannon, R., Shapiro, C., Hook, E., Alter, M., & Quinn, T. (1994). Hepatitis C, Hepatitis B, and human immunodeficiency virus infections among non-intravenous 43 drug-using patients attending clinics for sexually transmitted diseases. Journal of Infectious Diseases, 169(5), 990-995. Thorpe, L., Ouellet, L., Hershow, R., Bailey, S., Williams, I., Williamson, J., . . . Garfein, R. (2002). Risk of Hepatitis C virus infection among young adult injection drug users who share injection equipment. American Journal of Epidemiology, 155(7), 645-653. Tohme, R., & Holmberg, S. (2012). Transmission of Hepatitis C virus infection through tattooing and piercing: A critical review. Clinical Infectious Diseases, 54(8), 11671178. United States Department of Health & Human Services (HHS). Combating the silent epidemic of viral Hepatitis: Action plan for the prevention, care & treatment of viral Hepatitis. (2011). Retrieved from http://www.hhs.gov/ash/initiatives/Hepatitis/index.html van de Laar, T., van der Bij, A., Prins, M., Bruisten, S., Brinkman, K., Ruys, T., . . . Coutinho, R. (2007). Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. Journal of Infectious Diseases, 196(2), 230-238. Weinbaum, C., Sabin, K., & Santibanez, S. (2005). Hepatitis B, Hepatitis C, and HIV in correctional populations: A review of epidemiology and prevention. AIDS, 19(Suppl 3), 41-46. Williams, I., Bell, B., Kuhnert, W., & Alter, M. (2011). Incidence and transmission patterns of acute Hepatitis C in the United States, 1982-2006. Archives of Internal Medicine, 171(3), 242-248. Wolitski, R., & the Project START Writing Group. (2006). Relative efficacy of a multisession sexual risk-reduction intervention for young men released from prisons in 4 states. American Journal of Public Health, 96(10), 1854-1861. World Health Organization. (2007). Effectiveness of interventions to manage HIV in prisons Provision of condoms and other measures to decrease sexual transmission. Retrieved from http://www.who.int/hiv/idu/Prisons_condoms.pdf